Net income increased 25.5%
Net income changed +25.5% from the comparable as-filed period.
-$173.4M→-$129.3M2 prior comparisons
GROSSPATTERN / DETERMINISTIC EVIDENCE / V3
Search securities →BHVN financial changes
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Current liabilities decreased 44.5%
Current liabilities changed -44.5% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
$113.0M→$62.8M4 prior comparisons
Stockholders' equity decreased 472.5%
Stockholders' equity changed -472.5% from the comparable as-filed period.
-$17.2M→-$98.2M3 prior comparisons
Research & development decreased 27.9%
Research & development changed -27.9% from the comparable as-filed period.
$141.2M→$101.9M2 prior comparisons
Cash & equivalents decreased 48.2%
Cash & equivalents changed -48.2% from the comparable as-filed period.
$184.8M→$95.8M2 prior comparisons
Working capital / assets moved 265 bp lower
Working capital / assets changed -265 basis points from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
51.47%→48.83%4 prior comparisons
Stock-based compensation decreased 13.5%
Stock-based compensation changed -13.5% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
$21.5M→$18.6M2 prior comparisons
Capital expenditure changed across a low base
Capital expenditure changed +1284.6% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a low base.
$13,000→$180,0002 prior comparisons
Current ratio increased 6.6%
Current ratio changed +6.6% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
2.86→3.054 prior comparisons
Capital expenditure increased 94.8%
Capital expenditure changed +94.8% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
$233,000→$454,0003 prior comparisons
Research & development decreased 45.3%
Research & development changed -45.3% from the comparable as-filed period.
$184.4M→$100.8M2 prior comparisons
Cash & equivalents increased 43.6%
Cash & equivalents changed +43.6% from the comparable as-filed period.
$165.8M→$238.0M2 prior comparisons
Stockholders' equity decreased 90.9%
Stockholders' equity changed -90.9% from the comparable as-filed period.
$134.6M→$12.2M3 prior comparisons
Current liabilities decreased 49.6%
Current liabilities changed -49.6% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
$124.3M→$62.7M4 prior comparisons
Working capital decreased 33.3%
Working capital changed -33.3% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
$350.5M→$233.9M4 prior comparisons
Current ratio increased 23.9%
Current ratio changed +23.9% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
3.82→4.734 prior comparisons
Stock-based compensation decreased 7.9%
Stock-based compensation changed -7.9% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
$20.8M→$19.2M2 prior comparisons
Working capital / assets moved 59 bp lower
Working capital / assets changed -59 basis points from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
63.68%→63.09%4 prior comparisons
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.